Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04432298 · ClinicalTrials.gov registry record · Phase 2
Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Participants With Acute COVID-19 Disease
A Phase 2 study, sponsored by Kyntra Bio.
- Terminated
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT04432298 is a Phase 2 study that was terminated before completion, run by Kyntra Bio. The registered enrollment target is 22 participants.
The verdict
NCT04432298, a Phase 2 study, was terminated before completion, sponsored by Kyntra Bio.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
This study evaluates the efficacy and safety of intravenous (IV) infusions of pamrevlumab when compared with placebo in participants who are hospitalized with acute COVID-19 disease.
Interventions
- DRUG Placebo
- DRUG Pamrevlumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2020-06-20 |
| Est. Completion | 2021-03-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04432298
The ClinicalTrials.gov registry entry for NCT04432298 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kyntra Bio, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04432298 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04432298 about?
NCT04432298 is a clinical study titled "Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Participants With Acute COVID-19 Disease". This study evaluates the efficacy and safety of intravenous (IV) infusions of pamrevlumab when compared with placebo in participants who are hospitalized with acute COVID-19 disease.
What is the current status of trial NCT04432298?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2020-06-20. Estimated completion is 2021-03-22.
What interventions are being tested in trial NCT04432298?
The interventions under investigation include: Placebo (DRUG), Pamrevlumab (DRUG).
Who is sponsoring clinical trial NCT04432298?
This trial is sponsored by Kyntra Bio, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.